Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

VITASPRING BIOMEDICAL CO. LTD.

CIK 1697884 VSBC·Commercial Physical And Biological Research · All EDGAR filings ↗

Progression

  1. Material weakness 10-Q
  2. Revenue recognition change 10-K +146d
  3. Finance chief departure 8-K +94d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure high Filing comparison

VITASPRING BIOMEDICAL CO. LTD.'s Chief Financial Officer departed with no named successor

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
high
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Revenue recognition change beta Filing comparison

VITASPRING BIOMEDICAL CO. LTD. changed its revenue recognition disclosure

The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
Evidence
New language
The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract., (v) Recognize revenue when the Company satisfies a performance obligation.
Prior filed
2026-05-06
Prior form
10-Q
Similarity
0.471
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
  • (v) Recognize revenue when the Company satisfies a performance obligation.

Source filing ↗ Prior filing ↗

Revenue recognition change beta Filing comparison

VITASPRING BIOMEDICAL CO. LTD. changed its revenue recognition disclosure

The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
Evidence
New language
The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract., (v) Recognize revenue when the Company satisfies a performance obligation.
Prior filed
2026-03-12
Prior form
10-K
Similarity
0.515
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
  • (v) Recognize revenue when the Company satisfies a performance obligation.

Source filing ↗ Prior filing ↗

Material weakness high Filing comparison

VITASPRING BIOMEDICAL CO. LTD. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

GAAP and SEC reporting requirements. This deficiency increased the risk of material misstatements in the financial reporting process. Remediation Plan We are committed to improving our internal control environment. To remediate the identified material weakness, we plan to evaluate and enhance our internal control procedures and, as resources permit, hire additional qualified personnel or engage external consultants with relevant expertise in financial reporting and SEC compliance. We intend to enhance our internal…
Evidence
Current state
material_weakness
Current state label
Material weakness in internal control
Direction
newly reported
Prior filed
2022-12-21
Prior form
10-Q
Prior state
effective
Prior state label
Internal control reported effective
Remediation stated
Yes
Severity
high
Source
Item 9A internal control conclusion, compared with the prior filing
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗